Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

61.30 +1.39 (+2.32%)
Official Closing Price Updated: 4:10 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study. 
Via Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
3 Magnificent Stocks to Buy and Hold Forever
Via The Motley Fool
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT: Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Market Briefing For Monday, Feb. 3, 2025
As to the market, at the moment it is being reactive to tariffs, news of which of course aborted the effort at finishing January on a strong note. It's that basic. 
Via Talk Markets
Topics Commodities Stocks / Equities World Trade
Exposures Tariff
Top Picks For 2025: Skye Bioscience
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects.... 
Via Talk Markets
Topics Stocks / Equities
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Via The Motley Fool
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Investors should take notice of NYSE:NVO—it offers a great deal for the fundamentals it presents.
Take a closer look at NOVO-NORDISK A/S-SPONS ADR , a remarkable value stock. NYSE:NVO excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial’s Design – Hagens Berman
From Hagens Berman Sobol Shapiro LLP
Via GlobeNewswire
NOVO NORDISK ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Exposures Political
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
NVO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
5 Monster Stocks to Hold for the Next 10 Years
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich. 
Via The Motley Fool
Ozempic Receives FDA Approval To Treat Kidney Disease
The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease in patients who also have type 2 diabetes. 
Via Benzinga
Exposures Product Safety
NVO Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire
How Ozempic And Legal Weed Are Changing What America Eats
Ozempic curbs appetites, while cannabis legalization fuels munchies. Explore their public health impacts. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
What Does the Future Hold for Eli Lilly?
Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future. 
Via MarketBeat
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.